Sotera Health Co (SHC): Results of Operations and Financial Condition
Sotera Health Co (SHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook • Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 • Q2 2026 net income of $54 million or $0.19 per diluted share, comp
How this was made
The 30-second read
Why it matters
The filing combines an earnings beat-style update (higher Adjusted EPS and EBITDA) with a guidance raise and balance-sheet/leverage improvements, creating a clear near-term repricing catalyst.
Market read
Guidance increases plus strong Q2 operating cash flow and improved leverage/liquidity are likely to drive immediate investor focus on FY 2026 earnings power and risk assumptions.
What to watch
The outlook explicitly depends on supply chain continuity and regulatory landscape uncertainties; any adverse change in EO or Cobalt-60 availability could pressure future results despite current momentum.
Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Q2 net revenues increased 9.2%, Adjusted EBITDA increased 10.0%, Adjusted EPS increased 30%, all three operating segments posted revenue growth, and the Company raised its full-year 2026 net revenues and Adjusted EBITDA outlook.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q2 2026 net revenues growthGAAP | 9.2% | – | 9.2% |
| Q2 2026 net revenues growth, constant currency basisnon-GAAP | 8.0% | – | 8.0% |
| Q2 2026 net incomeGAAP | $54 million | – | – |
| Q2 2026 diluted earnings per shareGAAP | $0.19 per diluted share | – | – |
| Q2 2026 Adjusted EBITDA growthnon-GAAP | 10.0% | – | 10.0% |
| Q2 2026 Adjusted EBITDA growth, constant currency basisnon-GAAP | 8.7% | – | 8.7% |
| Q2 2026 Adjusted EBITDA marginnon-GAAP | 51.6% | – | – |
| Q2 2026 Adjusted EPSnon-GAAP | $0.26 | – | 30% |
| Q2 2026 net cash provided by operating activitiesGAAP | $88 million | – | – |
| June 30, 2026 Net Leverage Rationon-GAAP | 3.0x | – | – |
| Sterigenics Q2 2026 segment incomeother | $118 million | – | 9.6% |
| Sterigenics first six months of 2026 segment incomeother | $215 million | – | 9.6% |
| Nordion Q2 2026 segment incomeother | $28 million | – | 19.2% |
| Nordion first six months of 2026 segment incomeother | $52 million | – | 26.4% |
| Nelson Labs Q2 2026 segment incomeother | $20 million | – | 0.6% |
| Nelson Labs first six months of 2026 segment incomeother | $34 million | – | -4.9% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| SterigenicsSecond-quarter net revenues growth was driven by favorable pricing, improved volume/mix and a foreign currency benefit. | $212 million | – | 8.6% |
| NordionSecond-quarter net revenues growth was driven by improved volume/mix, primarily due to the timing of Cobalt-60 harvests and favorable pricing, partially offset by foreign currency. | $49 million | – | 15.8% |
| Nelson LabsSecond-quarter net revenues and segment income growth were driven by favorable pricing, improved volume/mix and a foreign currency benefit. | $61 million | – | 6.3% |
| Sterigenics, first six months of 2026Constant currency net revenues increased 6.6%. | $398 million | – | 9.1% |
| Nordion, first six months of 2026Constant currency net revenues increased 20.8%. | $91 million | – | 21.6% |
| Nelson Labs, first six months of 2026Constant currency net revenues improved 0.9%. | $113 million | – | 2.9% |
FY 2026 outlook
- Revenue$1.236 billion to $1.254 billion, representing constant currency growth of 5.25% to 6.75% and an estimated 100 basis points of foreign currency benefit
- Tax rate27.0% to 28.0%
- NoteAdjusted EBITDA range raised to $634 million to $643 million, representing constant currency growth of 5.75% to 7.25% and an estimated 100 basis points of foreign currency benefit
- NoteInterest expense improved to a range of $135 million to $142 million
- NoteAdjusted EPS improved to a range of $0.95 to $1.01
- NoteA weighted-average fully diluted share count in the range of 289 million to 291 million shares
- NoteCapital expenditures in the range of $200 million to $225 million
What drove it
- Sterigenics revenue growth reflected favorable pricing, improved volume/mix and a foreign currency benefit.
- Nordion growth reflected improved volume/mix, primarily due to the timing of Cobalt-60 harvests, and favorable pricing, partially offset by foreign currency.
- Nelson Labs growth reflected favorable pricing, improved volume/mix and a foreign currency benefit.
- All three business units reported revenue growth in Q2 2026.
- The Company cited strong first-half performance and confidence in the remainder of the year in raising its full-year 2026 outlook.
Concerns
- Nelson Labs segment income margin was impacted by higher costs.
- Inflation partially offset segment income and segment income margin benefits at Sterigenics and Nordion.
- The outlook incorporates assumptions regarding supply chain continuity, particularly for the supply of ethylene oxide and Cobalt-60, and inflationary trends affecting energy prices and labor supply.
- The Company identified potential uncertainty from changes to the regulatory landscape, restructuring items and certain fair value measurements.
- The filing cites risks related to ethylene oxide litigation, environmental, health and safety regulations, supply availability, foreign currency exchange rates, inflation and tariffs.
What to watch
- Execution against the raised FY 2026 net revenues range of $1.236 billion to $1.254 billion.
- Execution against the raised FY 2026 Adjusted EBITDA range of $634 million to $643 million.
- Whether Nelson Labs can improve its segment income margin following the impact from higher costs.
- Availability and pricing of ethylene oxide and Cobalt-60.
- Progress in maintaining the long-term net leverage ratio target range of 2.0x to 3.0x.
- Capital expenditures in the range of $200 million to $225 million.
Balance sheet and cash flow
- Net cash provided by operating activities of $88 million
- As of June 30, 2026, Sotera Health had $2.2 billion of total debt, and $357 million in unrestricted cash and cash equivalents.
- As of December 31, 2025, Sotera Health had $2.2 billion in total debt and $345 million in unrestricted cash and cash equivalents.
- Available liquidity increased to approximately $950 million.
- The Company had no outstanding borrowings under its $600 million revolving credit facility.
- Repriced term loan, saving approximately $3.5 million of annual interest expense.
- Net Leverage Ratio improved to 3.0x, achieving the Company’s long-term net leverage ratio target range of 2.0x to 3.0x.
Analysis
Sotera Health reported broad Q2 growth, with net revenues increasing 9.2%, or 8.0% on a constant currency basis. Net income was $54 million, compared to $8 million in Q2 2025, while diluted earnings per share were $0.19 per diluted share, compared to $0.03 per diluted share. Adjusted EBITDA increased 10.0%, or 8.7% on a constant currency basis, and the Adjusted EBITDA margin expanded to 51.6%. Adjusted EPS was $0.26, up 30% per diluted share.
All three segments contributed to revenue growth. Sterigenics net revenues increased 8.6% to $212 million, supported by favorable pricing, improved volume/mix and foreign currency. Nordion was the fastest-growing segment, with net revenues up 15.8% to $49 million, driven by volume/mix associated primarily with the timing of Cobalt-60 harvests and favorable pricing. Nelson Labs net revenues grew 6.3% to $61 million, with pricing, volume/mix and foreign currency contributing.
Profitability improved most visibly at Sterigenics and Nordion. Sterigenics segment income increased 9.6% to $118 million and Nordion segment income increased 19.2% to $28 million. Nelson Labs segment income increased 0.6% to $20 million, but its segment income margin was impacted by higher costs. For the first six months of 2026, Nelson Labs segment income decreased 4.9% to $34 million despite net revenue growth of 2.9% to $113 million, making cost recovery and margin progression at that business a key operating focus.
Cash generation and leverage improved. Net cash provided by operating activities was $88 million. The Company ended June 30, 2026 with $2.2 billion of total debt and $357 million in unrestricted cash and cash equivalents, while available liquidity increased to approximately $950 million. The Net Leverage Ratio improved to 3.0x, reaching the stated long-term target range of 2.0x to 3.0x. Sotera Health also repriced its term loan, saving approximately $3.5 million of annual interest expense.
Management raised full-year 2026 net revenues guidance to $1.236 billion to $1.254 billion and Adjusted EBITDA guidance to $634 million to $643 million. The outlook calls for constant currency net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%, each with an estimated 100 basis points of foreign currency benefit. The guide also includes interest expense of $135 million to $142 million, a tax rate applicable to Adjusted Net Income of 27.0% to 28.0%, Adjusted EPS of $0.95 to $1.01, and capital expenditures of $200 million to $225 million.
Management, verbatim
We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units.
Alton Shader, Chief Executive Officer
Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook.
Alton Shader, Chief Executive Officer
Not in the filing
stated, not guessed- Q2 2026 total net revenues dollar amount
- Q2 2026 total net revenues prior-year dollar amount
- Q2 2026 GAAP gross profit and gross margin
- Q2 2026 GAAP operating income and operating margin
- Q2 2026 Adjusted EBITDA dollar amount
- Q2 2026 Adjusted EBITDA prior-year dollar amount
- Q2 2026 Adjusted EPS prior-year value
- Q2 2026 free cash flow
- Quarterly capital expenditures
- Share repurchases and dividends
- Prior-quarter consolidated comparisons
- Previous-release outlook for comparison
- Forward gross margin guidance
- Forward operating expenses guidance
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Sotera Health filed an SEC Form 8-K (Item 2.02) with Q2 and first-half 2026 results and an updated full-year 2026 outlook.
Ticker impact
Sotera Health raised FY 2026 net revenue growth to 5.25% to 6.75% and Adjusted EBITDA growth to 5.75% to 7.25% after strong Q2 results.
Likely positive bias for the stock on open, with follow-through dependent on how investors price the raised outlook versus prior expectations.
This is a primary-source filing with quantified Q2 performance (net revenues, net income, Adjusted EPS/EBITDA) and explicit FY 2026 outlook increases, alongside leverage/liquidity metrics and a refinancing action (term loan repricing).
Market effects
Reinforces demand durability in sterilization and lab testing services, potentially supporting sentiment for healthcare services providers tied to regulated end-markets.
Limited direct regional spillover; primarily a US-listed single-name catalyst.
Global operations and constant-currency growth metrics suggest resilience despite FX and inflation assumptions.
Counterpoint
Raised guidance may already embed favorable pricing and volume/mix; investors could focus on inflation and supply continuity risks (EO and Cobalt-60) that could cap upside.
Key entities
- public_companySotera Health Company
Nasdaq-listed sterilization solutions and lab testing/advisory provider that reported Q2 2026 results and raised FY 2026 outlook.
- business_segmentSterigenics
Sotera Health segment reporting high-single-digit constant-currency revenue growth and margin improvement.
- business_segmentNordion
Sotera Health segment reporting double-digit constant-currency revenue growth driven by Cobalt-60 harvest timing and pricing.
- business_segmentNelson Labs
Sotera Health segment reporting mid-single-digit constant-currency revenue growth with margin impacted by higher costs.
